Knowledge Center

Membership Resources


Join the National Lipid Association, focused on enhancing the science and practice of lipidology to promote optimal cardiometabolic health.

After making your filter selections, please scroll down to see results.

Filters
Clear All
Results 358
Podcasts

S6E4: Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association

Listen to Dr. Alan Brown discuss the latest FCS paper with Dr. Fiza Javed and Dr. Nivedita Patni.

Listen Now | 51:49 |
Infographics

Treating Hypercholesterolemia in Patients Aged 75 and Older Without Established Atherosclerotic Cardiovascular Disease

Read More |

National Lipid Association and American Society for Preventive Cardiology Release Joint Expert Consensus on Chylomicronemia Management

The National Lipid Association (NLA), in collaboration with the American Society for Preventive Cardiology (ASPC), has released a Joint Expert Clinical Consensus providing new guidance…

Read More |
Articles

Recognition and Management of Persistent Chylomicronemia: A Joint Expert Clinical Consensus by the National Lipid Association and the American Society for Preventive Cardiology

Patients with persistent chylomicronemia and alarm features have a very high risk of acute pancreatitis, similar to FCS.

Read More |
Videos & Webinars

The Lipid Panel – CAD: What is Plaque? How do we measure and why?

Watch Now |
Podcasts

S6E3: Diets and Supplements

Listen to the latest podcast with Anna Biggins MPH, RDN, LD and Lauren Williams MCN, RDN, LD discussing recent fad diets and supplements.

Listen Now | 34:32 |
Articles

Familial Chylomicronemia Syndrome: An Expert Clinical Review from the National Lipid Association

Familial chylomicronemia syndrome (FCS) is a rare autosomal recessive disorder characterized by extreme hypertriglyceridemia and a high risk of recurrent acute pancreatitis.

Read More |
Podcasts

S6E2: From Research to Reality: Advancing FCS Therapy

Listen to Dr. Jones speak with Shannon Christen about FCS research and therapies and recent developments.

Listen Now | 30:22 |